- Home
- INSP vs VKTX Comparison
INSP vs VKTX Comparison
Compare INSP & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSP
- VKTX
- Stock Information
- Founded
- INSP 2007
- VKTX 2012
- Country
- INSP United States
- VKTX United States
- Employees
- INSP N/A
- VKTX N/A
- Industry
- INSP Medical/Dental Instruments
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- INSP Health Care
- VKTX Health Care
- Exchange
- INSP Nasdaq
- VKTX Nasdaq
- Market Cap
- INSP 3.8B
- VKTX 3.5B
- IPO Year
- INSP 2018
- VKTX 2015
- Fundamental
- Price
- INSP $126.01
- VKTX $32.68
- Analyst Decision
- INSP Buy
- VKTX Strong Buy
- Analyst Count
- INSP 12
- VKTX 13
- Target Price
- INSP $209.17
- VKTX $86.92
- AVG Volume (30 Days)
- INSP 603.9K
- VKTX 4.0M
- Earning Date
- INSP 08-04-2025
- VKTX 07-23-2025
- Dividend Yield
- INSP N/A
- VKTX N/A
- EPS Growth
- INSP N/A
- VKTX N/A
- EPS
- INSP 2.17
- VKTX N/A
- Revenue
- INSP $840,111,000.00
- VKTX N/A
- Revenue This Year
- INSP $20.61
- VKTX N/A
- Revenue Next Year
- INSP $17.32
- VKTX $338.60
- P/E Ratio
- INSP $58.20
- VKTX N/A
- Revenue Growth
- INSP 27.11
- VKTX N/A
- 52 Week Low
- INSP $123.25
- VKTX $18.92
- 52 Week High
- INSP $225.00
- VKTX $81.73
- Technical
- Relative Strength Index (RSI)
- INSP 43.07
- VKTX 58.37
- Support Level
- INSP $128.18
- VKTX $32.02
- Resistance Level
- INSP $133.95
- VKTX $34.60
- Average True Range (ATR)
- INSP 4.49
- VKTX 1.75
- MACD
- INSP 0.04
- VKTX -0.08
- Stochastic Oscillator
- INSP 25.79
- VKTX 43.33
About INSP Inspire Medical Systems Inc.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.